Cagrilintide + Semaglutide
Dual amylin/GLP-1 combination — superior weight loss through complementary mechanisms.
14.9%
Avg body weight reduction
68wk
STEP-1 trial duration
FDA
Reviewed mechanism
Cagrilintide (amylin analog) combined with Semaglutide (GLP-1 agonist) targets weight loss through two independent peptide pathways — additive effects vs. GLP-1 alone.
15.6% Weight Loss
Phase 2 CagriSema trials showed 15.6% weight reduction — surpassing semaglutide-alone comparators.
Dual Mechanism
Amylin + GLP-1 target different satiety circuits — genuinely additive effects at the neural level.
Phase 3 Ongoing
REDEFINE Phase 3 trials represent the most advanced dual-agonist program in metabolic medicine.
Cagrilintide + Semaglutide: The Dual-Pathway Weight Loss Protocol
Mechanism · Evidence · Application
This combination product contains both Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist) — two peptides that act through distinct but complementary mechanisms to produce weight loss effects that appear additive or even synergistic.
Cagrilintide: The Amylin Component
Cagrilintide is a long-acting analog of amylin — a peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. Amylin signals satiety through the area postrema in the brain, slows gastric emptying, and suppresses post-meal glucagon release. Natural amylin has a half-life of minutes; cagrilintide has been modified for a ~7-day half-life, enabling once-weekly dosing.
Amylin and GLP-1 activate distinct and complementary neural satiety pathways — acting on different brainstem and hypothalamic circuits to reduce food intake from multiple angles simultaneously.
CagriSema Clinical Data
In Phase 2 trials, the CagriSema combination (cagrilintide + semaglutide) demonstrated weight loss of approximately 15.6% over 32 weeks — numerically superior to semaglutide alone in the same timeframe. Phase 3 trials (REDEFINE) are currently underway.
The combination also showed improvements in: - Fasting glucose and HbA1c - Blood pressure and lipid profiles - Liver fat reduction
Metabolic & Weight Loss Results
Dual-pathway satiety — amylin and GLP-1 activate independent brain satiety circuits
~15.6% weight loss in Phase 2 trials — superior to GLP-1 alone
Once-weekly dosing for both components due to matched half-lives
Improved glycemic control through complementary insulin-regulating mechanisms
Enhanced cardiovascular risk factor reduction vs. single-agent protocols
Amylin suppresses post-meal glucagon — reduces blood glucose spikes
Additive satiety effects with fewer side effects than dose-escalating a single GLP-1
Weight Loss Protocol Guide
Cagrilintide + Semaglutide Protocol Guide
Standard Research Protocol:
· Dose: 2.4mg cagrilintide + 2.4mg semaglutide once weekly (from this 5+5mg vial)
· Route: Subcutaneous injection (abdomen, thigh, or upper arm)
· Escalation: Begin at lower doses and escalate over 16 weeks to maintenance
· Duration: 32+ weeks for full body composition effects
Injection Notes:
· Once-weekly injection of the combination
· Same day each week recommended for consistent plasma levels
· Follow standard GLP-1 nausea management protocol during dose escalation
Cagrilintide + Semaglutide
Apollo Peptides Sciences
$109.99
Buy from ApolloAffiliate link · supports PeptidesClav
Body Composition
Dual amylin/GLP-1 combination — superior weight loss through complementary mechanisms.
Quality Assurance
HPLC Testing
Purity verified per batch
Mass Spectrometry
Molecular identity confirmed
Certificate of Analysis
Publicly available
US-Based Supplier
Apollo Peptides Sciences
Synergistic Combinations
Stack Cagrilintide + Semaglutide With
Ready to Start?
Begin your Cagrilintide + Semaglutide protocol
Source from Apollo Peptides Sciences — HPLC-tested, mass-spectrometry verified, with a Certificate of Analysis per batch.
Shop Cagrilintide + Semaglutide at Apollo